{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059392","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.495494+00:00","generated_at":"2026-06-08T21:21:34.879976+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ORIC reports Q3 2023 net loss; cash $256.2M; ORIC-114 CNS responses","bullets":["Cash, cash equivalents and investments $256.2M as of Sept 30, 2023; expected to fund operations into late 2025.","R&D expenses $22.4M in Q3 2023, up from $14.7M in Q3 2022 due to pipeline advancement.","ORIC-114 Phase 1b data at ESMO showed CNS complete response in EGFR exon 20 NSCLC patient; favorable safety.","Initial ORIC-533 data in multiple myeloma to be presented at ASH December 2023.","ORIC-944 initial Phase 1b data in prostate cancer expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059392","json":"https://secwatch.observer/filing/0000950170-23-059392.json","markdown":"https://secwatch.observer/filing/0000950170-23-059392.md","text":"https://secwatch.observer/filing/0000950170-23-059392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/0000950170-23-059392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/oric-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:21:34.879976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e4584b4c612b571e7b3ef46bb04dbff45fe1088","claim":"Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/0000950170-23-059392-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}